Pricing Log in Create free account
Monday 2 November 2026 Export ARVN’s income statement to Excel — free account

Arvinas, Inc.

ARVN Healthcare Biotechnology

Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024.

Revenue
+1,014.7%
EPS
+410.7%
Free cash flow
+49.8%
Total debt
−40.0%

Quarter to June 2026, against a year earlier

7.56 0.30 −3.82%
Market cap
$513.9M
P/E
39.5×
Fwd P/E
−786×
Dividend yield
—
F-score
5/9
Altman Z
−0.61
Beneish M
−1.60
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.27
Sold, $m 1.42
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 1 — — — — — — — —
Sell — — 9 1 — 6 2 — — — — —
Insider Ownership 9.57%

Capital & Financial Ratios $m

Size
Market Cap 513.94
Revenue ttm 316.70
Net income ttm 9.30
Free cash flow ttm (208.80)
Net debt Q (567.60)
Valuation
P/E 39.48 (above 35: high)
Forward P/E (786.00) (negative: loss-making)
Price / sales 1.55
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.87
Financial health
Current ratio Q 7.91 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (7.39)
Growth
Revenue growth Q +1,014.73% (above 0%: growing)
Operating income growth Q +329.51% (above 0%: growing)
EPS, this year +97.23% (at or above 15%: strong)
EPS, next year A −10,250.45% (below 0%: weak)
Revenue, next year A +12.95% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A −23.43% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.2×, against a ten-year median of 8.3×; over the ten years it ranged from −4.5× in 2018 to 174× in 2021.
P/S against its own 10 years 6.54%
10-year low 10-year high
P/B against its own 10 years 4.21%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,267 1,039 685 568
Receivables 7 14 6 54
Inventory — — — —
Other — — — —
1,280 1,067 701 652
2023 2024 2025 Q'26
Payables 92 72 70 52
ST’ Debt — — — —
Other — — — 28
257 230 143 83

Compound Annual Growth %

10y 5y 3y
Sales — 58.93% 25.96%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (7.54%) (8.42%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.24 Actual 2.58

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.75 −0.48 Beat by 0.27
Q4 FY25 −0.55 −1.10 Miss by 0.55
Q1 FY26 −0.95 −0.90 Beat by 0.05
Q2 FY26 −0.24 2.58 Beat by 2.82
Q3 FY26 −0.80 — Reports 3 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.90) 2.58 — — —
’25 1.14 (0.84) (0.48) (1.04) (1.14)
’24 (0.97) (0.49) (0.68) (0.63) (2.77)
’23 (1.54) (1.25) (1.18) (2.53) (6.62)
’22 (1.20) (1.32) (1.24) (1.56) (5.31)
’21 (0.84) (1.03) (0.94) (1.00) (3.82)
’20 (0.56) (0.65) (0.79) (0.99) (3.02)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 16 250 — — —
’25 189 22 42 10 263
’24 25 77 102 59 263
’23 33 55 35 (43) 79
’22 27 34 33 38 131
’21 6 6 9 33 54
’20 6 6 8 6 26
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (69) (48) — — —
’25 (89) (95) (59) (30) (274)
’24 (97) 50 (128) (84) (259)
’23 (91) (89) (85) (83) (348)
’22 (57) (79) (67) (71) (273)
’21 (39) (47) 682 (36) 559
’20 (17) (21) (22) (29) (90)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (70) (48) — — —
’25 (89) (97) (59) (31) (276)
’24 (98) 50 (129) (84) (261)
’23 (92) (89) (86) (83) (351)
’22 (59) (80) (69) (72) (280)
’21 (40) (48) 680 (38) 555
’20 (18) (23) (24) (31) (96)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 7 8 14 43 26 54 131 79 263 263 317 +50.4% 297 69 72 (34.9%)
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 97.16 0.0 pt
EBT (14) (24) (41) (46) (115) (184) (251) (364) (198) (80) 10 +21.0%
EBT margin, % (216.50) (317.32) (289.59) (106.05) (444.79) (343.47) (191.02) (463.57) (75.28) (30.65) 3.16 +185.9 pt
Net income (14) (24) (41) (70) (119) (191) (282) (367) (199) (81) 9 +21.2%
Per share, $
Per share, $ Revenue 3.51 4.00 1.52 1.31 0.66 1.07 2.47 1.41 3.66 3.70 4.89 +0.6%
Earnings (7.56) (15.08) (25.45) (2.13) (3.02) (3.82) (5.31) (6.62) (2.77) (1.14) 0.19 (19.0%)
Cash flow (10.22) 2.70 (1.71) (1.23) (2.27) 11.19 (5.14) (6.27) (3.61) (3.86) (3.19) (10.3%)
Capex (0.14) (0.53) (0.30) (0.19) (0.16) (0.09) (0.13) (0.05) (0.02) (0.03) (0.03) (16.5%)
Free cash flow (10.36) 2.16 (2.01) (1.43) (2.43) 11.09 (5.27) (6.32) (3.63) (3.89) (3.22) (10.3%)
Book value 12.66 0.13 14.50 6.89 16.26 15.63 10.62 11.89 7.81 6.12 8.68 (7.8%)
Shares, m 2 2 9 33 40 50 53 56 72 71 68 +49.5%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 39.48 0.0
P/S 0.00 0.00 8.45 31.44 129.53 76.62 13.51 32.30 5.23 3.20 1.55 30.0
P/B 0.00 0.00 0.89 5.96 5.22 5.25 3.14 3.84 2.45 1.94 0.87 2.9
EV/Sales 0.00 0.00 (4.51) 24.97 103.06 48.54 4.31 16.20 1.29 0.60 (0.24) 19.4
EV/FCF (0.46) (0.46) 3.41 (22.89) (27.77) 4.69 (2.02) (3.63) (1.31) (0.57) 0.37 (5.1)
Cash, $m
Cash, $m Operating cash flow (19) 5 (16) (41) (90) 559 (273) (348) (259) (274) (207) +34.2%
Capex 0 (1) (3) (6) (6) (5) (7) (3) (2) (2) (2) +24.9%
Free cash flow (20) 4 (19) (47) (96) 555 (280) (351) (261) (276) (209) +34.1%
Balance, $m
Balance, $m Working capital 27 48 173 258 654 1,291 945 1,023 838 558 570 +39.9%
Net debt (35) (39) (186) (279) (687) (1,506) (1,210) (1,266) (1,039) (685) (568) +39.1%
Shareholders’ equity 24 0 137 227 642 782 565 660 562 434 562 +37.9%
Returns, %
Returns, % ROA (23.54) (54.63) (180.25) (28.07) (23.41) (16.62) (19.82) (28.55) (16.60) (8.93) 1.17 +14.6 pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE 26.32 60.82 (635.93) (38.70) (27.46) (26.83) (41.96) (59.97) (32.56) (16.23) 1.59 (42.5) pt
People
People Employees — 72 83 133 179 280 415 445 430 246 — +16.6%
Revenue/emp, $m 0.00 0.11 0.17 0.32 0.14 0.19 0.32 0.18 0.61 1.07 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026

Arvinas, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR $524.8M — (loss-making) — (loss-making) −7.53% (below 0%: shrinking) n/m −31.52% (below 0%: shrinking) 0.00% 0.00% Compare
ARVN Arvinas, Inc. $513.9M 41.0× — (loss-making) +1,014.73% (above 0%: growing) n/m +49.79% (above 0%: growing) 96.40% 65.72%
OCS Oculis Holding AG $509.9M — (loss-making) — (loss-making) +23.96% (above 0%: growing) n/m −10.40% (below 0%: shrinking) 100.00% (7,603.42%) Compare
CTMX CytomX Therapeutics, Inc. $509.9M — (loss-making) — (loss-making) −92.40% (below 0%: shrinking) n/m −14.50% (below 0%: shrinking) 100.00% (1,677.08%) Compare
CBIO Crescent Biopharma, Inc. $500.7M — (loss-making) — (loss-making) +1,038,900.00% (above 0%: growing) n/m −7.04% (below 0%: shrinking) 100.00% 0.00% Compare
DMAC DiaMedica Therapeutics, Inc. $498.8M — (loss-making) — (loss-making) — n/m −6.75% (below 0%: shrinking) 0.00% 0.00% Compare
OVID Ovid Therapeutics $496.1M — (loss-making) — (loss-making) +463.85% (above 0%: growing) n/m −268.54% (below 0%: shrinking) 100.00% (2,141.61%) Compare
INDP Indaptus Therapeutics, Inc. $474.6M — (loss-making) — — n/m +52.03% (above 0%: growing) 0.00% 0.00% Compare
PHAT Phathom Pharmaceuticals, Inc. $466.6M — (loss-making) — (loss-making) +88.02% (above 0%: growing) n/m +96.86% (above 0%: growing) 79.68% (5.34%) Compare
Median of peers $499.8M — — +55.99% — −8.72% 89.84% (2.67%)

All 619 Biotechnology stocks →

Pay and ownership Proxy statement filed 29 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 6.53m 2.58m 13.96
2024 12.75m 3.23m 22.57
2023 7.63m 5.98m 48.46
2022 9.55m 6.68m 40.28
2021 12.60m 9.30m 96.71

Ownership

Directors and executive officers, together 7.30%
The Vanguard Group 12.96%
BlackRock, Inc. 8.41%
Pfizer, Inc. 5.36%
D.E. Shaw & Co., L.P. (and affiliated entities) 5.28%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Arvinas, Inc. (ARVN) Latest News

27 Oct

Impact 3 · · GlobeNewswire

26 Oct

Impact 3 · · Trefis

13 Oct

Impact 4 · · Zacks

7 Oct

Impact 3 · · GlobeNewswire

1 Oct

Impact 3 · · GlobeNewswire

28 Sep

Impact 4 ·

9 Sep

Impact 5 ·

3 Sep

Impact 3 ·

11 Aug

Impact 3 · · The Motley Fool transcript

4 Aug

Impact 3 · · Moby transcript
Impact 3 · · MarketBeat transcript
Impact 3 ·

16 Jun

Impact 3 ·

5 Jun

Impact 4 · · MarketBeat

4 Jun

Impact 3 · · GlobeNewswire

16 May

Impact 3 · · Simply Wall St.

15 May

Impact 4 · · Benzinga

14 May

Impact 4 · · Simply Wall St.
Impact 4 · · Simply Wall St.

13 May

Impact 4 · · Benzinga
Impact 4 · · Simply Wall St.
Impact 3 · · Moby transcript

12 May

Impact 4 · · GuruFocus.com
Impact 4 · · MarketBeat
Impact 4 · · biopharmadive.com
Impact 4 · · PR Newswire
Impact 4 ·
Impact 3 · · GlobeNewswire

6 May

Impact 4 · · GlobeNewswire

4 May

Impact 4 · · Business Wire
stockrow.com/ARVN · Data as of Oct 25, 2026 · For information only; not investment advice. · © 2026 stockrow.com